Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Phase contrast MRI (PC-MRI) is used clinically to measure velocities in the body, but systematic background phase errors caused by magnetic field imperfections corrupt the velocity measurements with offsets that limit clinical utility. This work aims to minimize systematic background phase errors in PC-MRI, thereby maximizing the accuracy of velocity measurements.
Methods: The MRI scanner's background phase errors from eddy currents and mechanical oscillations were modeled using the gradient impulse response function (GIRF). Gradient waveforms were then numerically optimized using the GIRF to create pulse sequences that minimize the background phase errors. The pulse sequences were tested in a static phantom where the predicted response could be compared directly to the measured background velocity. The optimized acquisitions were then tested in human subjects, where flow rates and background errors were compared to conventional PC-MRI.
Results: When using the GIRF-optimized gradient waveforms, the predicted background phase was within 0.6 [95% CI = -3.4, 5.4] mm/s of the measured background phase in a static phantom. Excellent agreement was seen for in vivo blood flow values (flow rate agreement = 0.96), and the background phase was reduced by 78.8 18.7%.
Conclusion: This work shows that using a GIRF to model the effects of magnetic field imperfections combined with numerically optimized gradient waveforms enables PC-MRI waveforms to be designed to produce a minimal background phase in the most time-efficient manner. The methodology could be adapted for other MRI sequences where similar magnetic field errors affect measurements.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11870205 | PMC |
| http://dx.doi.org/10.1002/mrm.30336 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Randomized trial of activated vitamin D for acute kidney injury prevention in critically ill patients.
JCI Insight
September 2025
Division of Nephrology, Boston University Chobanian & Avedisian School of Medicine, Boston, United States of America.
Background: Active vitamin D metabolites, including 25-hydroxyvitamin D (25D) and 1,25-dihydroxyvitamin D (1,25D), have potent immunomodulatory effects that attenuate acute kidney injury (AKI) in animal models.
Methods: We conducted a phase 2, randomized, double-blind, multiple-dose, 3-arm clinical trial comparing oral calcifediol (25D), calcitriol (1,25D), and placebo among 150 critically ill adult patients at high-risk of moderate-to-severe AKI. The primary endpoint was a hierarchical composite of death, kidney replacement therapy (KRT), and kidney injury (baseline-adjusted mean change in serum creatinine), each assessed within 7 days following enrollment using a rank-based procedure.
Hyperhomocysteinemia in chronic schizophrenia: prevalence, clinical correlates, and paradoxical associations with symptom severity.
Eur Arch Psychiatry Clin Neurosci
September 2025
Tianjin Anding Hospital, Institute of Mental Health, Psychiatric Medical Center of Tianjin University, Mental Health Center of Tianjin Medical University, 13 Liulin Road, Tianjin, 300222, China.
Background: Elevated homocysteine levels, known as hyperhomocysteinemia (HHcy), have been implicated in the pathophysiology of schizophrenia. Most prior studies focused on first-episode or acute-phase schizophrenia patients, leaving the prevalence, determinants, and clinical correlates of HHcy in chronic schizophrenia understudied. This study aims to investigate the prevalence and determinants of HHcy in patients with chronic schizophrenia, as well as its clinical correlates.
View Article and Find Full Text PDFFeasibility of a Gamified Mobile-Based Self-Management Intervention for Individuals With Nonspecific Chronic Lower Back Pain.
Nurs Res
September 2025
College of Nursing & Institute of Nursing Research, Korea University, Seoul, South Korea.
Background: Existing research fails to address the complex nature of nonspecific chronic lower back pain (cLBP ) despite its detrimental effect on economic, societal, and medical expenditures.
Objectives: We developed a nurse-led, mobile-delivered self-management intervention-Problem-Solving Pain to Enhance Living Well (PROPEL-M)-and evaluated its usability, feasibility, and initial efficacy for South Korean adults with nonspecific cLBP.
Methods: This study was composed of two phases: (a) lab and field usability testing for a gamified mobile device application; and (b) a pilot study employing a one-arm pre-test and post-test design among adults aged 18-60 years with nonspecific cLBP.
Assessment of patient satisfaction with percutaneous coronary angioplasty and clinical care experience: a qualitative study.
Minerva Cardiol Angiol
September 2025
Division of Cardiology, Vito Fazzi Hospital, Lecce, Italy.
Background: In the face of numerous studies concerning the technical advances of percutaneous coronary intervention [PCI] and clinical outcomes, only a few studies focus on patients' lived experiences after PCI. This study aims to explore patients' lived experiences after PCI, both in clinical terms and in terms of their perception of their health status, functional capacity, and autonomy at home.
Methods: A qualitative phenomenological, individual, semi-structured survey was conducted on a sample of 18 patients undergoing PCI.
Overall Survival with Amivantamab-Lazertinib in -Mutated Advanced NSCLC.
N Engl J Med
September 2025
Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
Background: Previous results from this phase 3 trial showed that progression-free survival among participants with previously untreated (epidermal growth factor receptor)-mutated advanced non-small-cell lung cancer (NSCLC) was significantly improved with amivantamab-lazertinib as compared with osimertinib. Results of the protocol-specified final overall survival analysis in this trial have not been reported.
Methods: We randomly assigned, in a 2:2:1 ratio, participants with previously untreated -mutated (exon 19 deletion or L858R substitution), locally advanced or metastatic NSCLC to receive amivantamab-lazertinib, osimertinib, or lazertinib.